NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis

Ionis Pharmaceuticals, Inc. (IONS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IONS

$58.09

−$0.04 (−0.07%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IONS with… →

IONS Key Statistics

As of Sep 4, 2026
Trading
Open
$58.36
Previous Close
$58.13
Day's Range
57.78–58.96
52-Week Range
50.01–86.74
Volume
2.59M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.42
Valuation
Market Cap
$9.65B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
27.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.48
Financials (FY)
Revenue (FY)
$943.71M+33.83%
Net Income (FY)
−$381.39M
Profit marginThe share of revenue left as profit after all costs and taxes.
−64.66%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
166.18M
1-Year Return
−2.12%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
3.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IONS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−26.57%
2025+126.29%
2024−30.90%
2023+33.94%
2022+24.12%
2021−46.18%
2020−6.41%
2019+11.75%
2018+7.48%
2017+5.16%
2016 (partial year)+33.19%

As of September 4, 2026.

IONS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$943.71M−$381.39M−40.4%
2024$705.14M−$453.90M−64.4%
2023$787.65M−$366.29M−46.5%
2022$587.37M−$269.72M−45.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$943.71M$927.80M−$381.72M−$381.39M−40.4%
2024$705.14M$693.92M−$475.11M−$453.90M−64.4%
2023$787.65M$778.51M−$353.73M−$366.29M−46.5%
2022$587.37M$573.25M−$410.19M−$269.72M−45.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IONS Valuation vs Biotechnology Median

Median of 656 stocks
MetricIONSBiotechnology medianvs median
P/S ratio11.0415.2628% below
Profit margin−64.66%0.00%64.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ionis Pharmaceuticals, Inc. (IONS) carries a market capitalisation of $9.65B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 1,480 employees.

The 52-week range on file runs from $50.01 to $86.74. IONS last closed at $58.09 on September 4, 2026. That is −$0.04 (−0.07%) against the previous close. The latest close sits 16.16% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $943.71M. That is +33.83% against the prior fiscal year, when revenue was $705.14M. The same year closed with a net loss of $381.39M. Profit margin runs at −64.66%. That is 64.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −3.48.

Across the 4 fiscal years on file, revenue moves from $587.37M in 2022 to $943.71M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 27.33. The price-to-sales ratio is 11.04. On price-to-sales that is 27.64% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −2.12%. Measured over 10 years, that is +7.03% a year compounded. The reported beta is 0.42. Annualized volatility over the trailing 10 years is 45.67%.

Growth & Income

No dividend is on file for IONS.

Across the complete calendar years on file, 2025 returned +126.29% and 2021 returned −46.18%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is −26.57% year to date.

Peer Comparison

Ionis Pharmaceuticals, Inc. (IONS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ionis Pharmaceuticals, Inc. IONS $9.65B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ionis Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Visit website →